Advanced prostate cancer: what's new in hormonal manipulation?

Br J Hosp Med. 1993;49(10):710-1, 714-5.

Abstract

Prostate cancer is the second most common cause of male cancer deaths in the UK. It is one of the few hormone-sensitive cancers and androgen ablation produces subjective and objective tumour regression in 70-80% of patients for a variable period. Orchidectomy remains the gold standard for treatment although there is an increasing number of equally effective medical alternatives.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists / administration & dosage
  • Androgen Antagonists / pharmacology
  • Androgen Antagonists / therapeutic use
  • Combined Modality Therapy
  • Gonadotropin-Releasing Hormone / analogs & derivatives
  • Humans
  • Male
  • Orchiectomy
  • Palliative Care
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Sexual Behavior / drug effects
  • Survival Rate

Substances

  • Androgen Antagonists
  • Gonadotropin-Releasing Hormone